Last reviewed · How we verify
Warfarin vs ASA
Warfarin vs ASA is a Anticoagulant (warfarin) and antiplatelet agent (aspirin) Small molecule drug developed by Hamilton Health Sciences Corporation. It is currently FDA-approved for Stroke prevention in atrial fibrillation, Thromboembolism prevention post-myocardial infarction, Venous thromboembolism prophylaxis and treatment.
This is a comparative analysis of two anticoagulant/antiplatelet agents: warfarin (a vitamin K antagonist) and aspirin (an antiplatelet agent), used to prevent thrombotic events.
Warfarin is used to treat conditions such as heart defects, aortic valve disease, and aortic valve insufficiency, as seen in clinical trials on ClinicalTrials.gov. Aspirin, on the other hand, is also studied in clinical trials on ClinicalTrials.gov for similar conditions, but its exact indications and comparisons to Warfarin are not specified in the provided facts.
At a glance
| Generic name | Warfarin vs ASA |
|---|---|
| Sponsor | Hamilton Health Sciences Corporation |
| Drug class | Anticoagulant (warfarin) and antiplatelet agent (aspirin) |
| Target | Vitamin K-dependent clotting factors (warfarin); cyclooxygenase (aspirin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) to reduce thrombus formation, while aspirin irreversibly inhibits platelet cyclooxygenase to prevent platelet aggregation. The comparison evaluates their relative efficacy and safety in preventing stroke and other thromboembolic events.
Approved indications
- Stroke prevention in atrial fibrillation
- Thromboembolism prevention post-myocardial infarction
- Venous thromboembolism prophylaxis and treatment
Common side effects
- Bleeding (major)
- Bleeding (minor)
- Gastrointestinal bleeding
- Intracranial hemorrhage
- Dyspepsia (aspirin)
Key clinical trials
- Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves (PHASE3)
- Anticoagulation for Aortic Bioprosthesis (ANTIPRO) (PHASE4)
- Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI) (PHASE3)
- Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death (NA)
- International Multi Centre Randomized Clinical Trial Of Anticoagulation In Children Following Fontan Procedures (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Warfarin vs ASA CI brief — competitive landscape report
- Warfarin vs ASA updates RSS · CI watch RSS
- Hamilton Health Sciences Corporation portfolio CI
Frequently asked questions about Warfarin vs ASA
What is Warfarin vs ASA?
How does Warfarin vs ASA work?
What is Warfarin vs ASA used for?
Who makes Warfarin vs ASA?
What drug class is Warfarin vs ASA in?
What development phase is Warfarin vs ASA in?
What are the side effects of Warfarin vs ASA?
What does Warfarin vs ASA target?
Related
- Drug class: All Anticoagulant (warfarin) and antiplatelet agent (aspirin) drugs
- Target: All drugs targeting Vitamin K-dependent clotting factors (warfarin); cyclooxygenase (aspirin)
- Manufacturer: Hamilton Health Sciences Corporation — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Stroke prevention in atrial fibrillation
- Indication: Drugs for Thromboembolism prevention post-myocardial infarction
- Indication: Drugs for Venous thromboembolism prophylaxis and treatment
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing